Document is current
Any future updates will be listed below
-
Authors
Castro-Dopico, Tomás https://orcid.org/0000-0002-6964-5478
Piot, Cécile
Buck, Michael D. https://orcid.org/0000-0002-9611-1199
Gandullo-Sánchez, Lucía
Lim, Kok Haw Jonathan https://orcid.org/0000-0002-6544-9218
Gonzales, Gerone A.
Rosendahl, Nikita https://orcid.org/0000-0002-5188-7487
Schulz, Oliver
Stainier, William https://orcid.org/0009-0003-6182-4003
Vash, Brian
Maiocco, Stephanie
Henry, Conor M.
Frederico, Bruno
Lee, Sonia
Zhang, Andy Bo https://orcid.org/0000-0002-4672-4181
Rogers, Neil C. https://orcid.org/0000-0001-8977-7585
Bordoloi, Jayanta
Roustan, Chloë
Kjaer, Svend https://orcid.org/0000-0001-9767-8683
Trikha, Mohit
Stauss, Hans https://orcid.org/0000-0003-4340-7911
Hazini, Ahmet
Radford, Kristen J. https://orcid.org/0000-0001-6512-6323
Tuong, Zewen Kelvin https://orcid.org/0000-0002-6735-6808
Canton, Johnathan
Mehta, Raj
Reis e Sousa, Caetano https://orcid.org/0000-0001-7392-2119
- License Information
-
More Information
Article History
Received: 24 September 2025
Accepted: 9 April 2026
First Online: 20 May 2026
Competing interests
: T.C.-D., L.G.-S., O.S., C.P., R.M. and C.R.S. are named inventors on patent applications on the use of Fc–DNGR-1 and anti-F-actin antibodies for immunotherapies, which are licensed to Adendra Therapeutics (Cross-Training Technology: Fc–DNGR-1 (WO2023203198A1); Cross-Training Technology: anti-F-actin antibody (WO2025163203A1)). B.V. and S.M. are employees of Apple Tree Partners, which provided seed funding for Adendra Therapeutics. R.M. and C.R.S. are Directors of and own shares in Adendra Therapeutics. C.R.S. sits on the Advisory Boards of Bicycle Therapeutics and Montis Biosciences. C.R.S. holds visiting professorships at Imperial College London and King’s College London and an honorary professorship at University College London, all unrelated to this work. The other authors declare no competing interests.
